{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T10:36:25Z","timestamp":1791023785043,"version":"4.1.0"},"reference-count":88,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1097\/spc.0000000000000013","type":"journal-article","created":{"date-parts":[[2013,10,23]],"date-time":"2013-10-23T17:11:23Z","timestamp":1382548283000},"page":"352-360","source":"Crossref","is-referenced-by-count":138,"title":["Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders"],"prefix":"10.1097","volume":"7","author":[{"given":"Rosamund C.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris K.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20211004","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1200\/JCO.2012.48.3149","article-title":"Clinical trials of cancer cachexia therapy, now and hereafter.","volume":"31","author":"Baracos","year":"2013","journal-title":"J Clin Onc"},{"key":"R3-5-20211004","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1139\/h2012-079","article-title":"A critical evaluation of body composition modalities used to assess adipose and skeletal muscle tissue in cancer.","volume":"37","author":"Di Sebastiano","year":"2012","journal-title":"Appl Physiol Nutr Metab"},{"key":"R4-5-20211004","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2012.06.011","article-title":"Cancer cachexia: mediators, signaling and metabolic pathways.","volume":"16","author":"Fearon","year":"2012","journal-title":"Cell Metab"},{"key":"R5-5-20211004","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nrclinonc.2012.209","article-title":"Understanding the mechanisms and treatment options in cancer cachexia.","volume":"10","author":"Fearon","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"R6-5-20211004","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/2044-5040-1-2","article-title":"Treating cancer cachexia to treat cancer.","volume":"1","author":"Lee","year":"2011","journal-title":"Skeletal Muscle"},{"key":"R7-5-20211004","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1517\/14656566.2012.734297","article-title":"Current pharmacotherapy options for cancer anorexia and cachexia.","volume":"13","author":"Maccio","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"R8-5-20211004","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2012.45.2722","article-title":"Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index.","volume":"31","author":"Martin","year":"2013","journal-title":"J Clin Oncol"},{"key":"R9-5-20211004","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1517\/14728214.2012.652946","article-title":"Editorial update on emerging drugs for cancer cachexia.","volume":"17","author":"Murphy","year":"2012","journal-title":"Expert Opin Emerg Drugs"},{"key":"R10-5-20211004","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/j.surg.2012.05.028","article-title":"Cachexia but not obesity worsens the postoperative outcome after pancreatoduodenectomy in pancreatic cancer.","volume":"152","author":"Pausch","year":"2012","journal-title":"Surgery"},{"key":"R11-5-20211004","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2174\/187153012802002910","article-title":"Cancer cachexia: molecular targets and pathways for diagnosis and drug intervention.","volume":"12","author":"Shum","year":"2012","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"R12-5-20211004","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1007\/s00535-013-0787-0","article-title":"Cancer cachexia - pathophysiology and management.","volume":"48","author":"Suzuki","year":"2013","journal-title":"J Gastroenterol"},{"key":"R13-5-20211004","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1177\/0884533612457949","article-title":"Importance of lean body mass in the oncologic patient.","volume":"27","author":"Tsai","year":"2012","journal-title":"Nutr Clin Pract"},{"key":"R14-5-20211004","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s13539-012-0075-5","article-title":"Predicting survival in cancer patients: the role of cachexia and hormonal, nutritional and inflammatory markers.","volume":"3","author":"Utech","year":"2012","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R15-5-20211004","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s13539-012-0087-1","article-title":"Cancer cachexia: impact, mechanisms and emerging treatments.","volume":"4","author":"Vaughan","year":"2013","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R16-5-20211004","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus.","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"key":"R17-5-20211004","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/SPC.0b013e328359b681","article-title":"Mechanisms for maintaining muscle.","volume":"6","author":"Banerjee","year":"2012","journal-title":"Curr Opin Support Palliat Care"},{"key":"R18-5-20211004","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s13539-012-0074-6","article-title":"Molecular and cellular mechanisms of skeletal muscle atrophy: an update.","volume":"3","author":"Fanzani","year":"2012","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R19-5-20211004","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s13539-010-0007-1","article-title":"Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training.","volume":"1","author":"Lenk","year":"2010","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R20-5-20211004","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s13539-011-0052-4","article-title":"Sarcopenia and cachexia: the adaptations of negative regulators of skeletal muscle mass.","volume":"3","author":"Sakuma","year":"2012","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R21-5-20211004","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1111\/febs.12253","article-title":"Mechanisms regulating skeletal muscle growth and atrophy.","volume":"280","author":"Schiaffino","year":"2013","journal-title":"FEBS J"},{"key":"R22-5-20211004","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/SPC.0b013e32834bddf9","article-title":"Targeting the myostatin signaling pathway to treat muscle wasting diseases.","volume":"5","author":"Han","year":"2011","journal-title":"Curr Opin Support Palliat Care"},{"key":"R23-5-20211004","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.drudis.2012.02.001","article-title":"Myostatin: more than just a regulator of muscle mass.","volume":"17","author":"Argiles","year":"2012","journal-title":"Drug Discov Today"},{"key":"R24-5-20211004","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s13539-011-0035-5","article-title":"The role of myostatin in muscle wasting: an overview.","volume":"2","author":"Elkina","year":"2011","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R25-5-20211004","doi-asserted-by":"crossref","first-page":"18117","DOI":"10.1073\/pnas.0505996102","article-title":"Regulation of muscle growth by multiple ligands signaling through activin type II receptors 2005.","volume":"13","author":"Lee","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R26-5-20211004","doi-asserted-by":"crossref","first-page":"21037","DOI":"10.1074\/jbc.M110.114959","article-title":"Characterization of the ligand binding functionality of the extracellular domain of the activin receptor type IIb.","volume":"285","author":"Sako","year":"2010","journal-title":"J Biol Chem"},{"key":"R27-5-20211004","doi-asserted-by":"crossref","first-page":"27313","DOI":"10.1074\/jbc.M112.377960","article-title":"Specificity and structure of a high affinity activin receptor-like kinase 1 (ALK1) signaling complex.","volume":"287","author":"Townson","year":"2012","journal-title":"J Biol Chem"},{"key":"R28-5-20211004","doi-asserted-by":"crossref","first-page":"40735","DOI":"10.1074\/jbc.M206379200","article-title":"The myostatin propeptide and the follistatin-related gene are inhibitory binding proteins of myostatin in normal serum.","volume":"277","author":"Hill","year":"2002","journal-title":"J Biol Chem"},{"key":"R29-5-20211004","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1210\/en.2006-0089","article-title":"Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins.","volume":"147","author":"Sidis","year":"2006","journal-title":"Endocrinol"},{"key":"R30-5-20211004","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.bbrc.2009.12.123","article-title":"Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia.","volume":"391","author":"Benny Klimek","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"R31-5-20211004","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.cell.2010.07.011","article-title":"Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival.","volume":"142","author":"Zhou","year":"2010","journal-title":"Cell"},{"key":"R32-5-20211004","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s13539-011-0049-z","article-title":"Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance.","volume":"3","author":"Busquets","year":"2012","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R33-5-20211004","doi-asserted-by":"crossref","first-page":"R716","DOI":"10.1152\/ajpregu.00121.2011","article-title":"Antibody-directed myostatin inhibition enhances muscle mass and function in tumor-bearing mice.","volume":"301","author":"Murphy","year":"2011","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"R34-5-20211004","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/nature01154","article-title":"Functional improvement of dystrophic muscle by myostatin blockade.","volume":"420","author":"Bogdanovich","year":"2002","journal-title":"Nature"},{"key":"R35-5-20211004","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2174\/156652312800840577","article-title":"Interference with myostatinActRIIB signaling as a therapeutic strategy for Duchenne muscular dystrophy.","volume":"12","author":"Amthor","year":"2012","journal-title":"Curr Gene Ther"},{"key":"R36-5-20211004","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.cell.2010.12.005","article-title":"Duchenne muscular dystrophy models show their age.","volume":"143","author":"Chamberlain","year":"2010","journal-title":"Cell"},{"key":"R37-5-20211004","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.pmr.2011.11.014","article-title":"The paradox of muscle hypertrophy in muscular dystrophy.","volume":"23","author":"Kornegay","year":"2012","journal-title":"Phys Med Rehabil Clin N Am"},{"key":"R38-5-20211004","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/mus.21944","article-title":"Soluble activin receptor type IIB increases forward pulling tension in the mdx mouse.","volume":"43","author":"Carlson","year":"2011","journal-title":"Muscle Nerve"},{"key":"R39-5-20211004","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/mt.2009.322","article-title":"Combination of myostatin pathway interference and dystrophin rescue enhances titanic and specific force in dystrophic mdx mice.","volume":"18","author":"Dumonceaux","year":"2010","journal-title":"Mol Ther"},{"key":"R40-5-20211004","first-page":"1287","article-title":"Targeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy.","volume":"178","author":"Pistilli","year":"2011","journal-title":"Am J Physiol"},{"key":"R41-5-20211004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0009176","article-title":"Systemic myostatin inhibition via liver-targeted gene transfer in normal and dystrophic mice.","volume":"5","author":"Morine","year":"2010","journal-title":"PLoS One"},{"key":"R42-5-20211004","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1089\/hum.2012.056","article-title":"Combined effect of AAV-U7-induced dystrophin exon skipping and soluble activin type IIB receptor in mdx mice.","volume":"23","author":"Hoogaars","year":"2012","journal-title":"Hum Gene Ther"},{"key":"R43-5-20211004","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.2353\/ajpath.2010.090932","article-title":"Antibody-directed myostatin inhibition improves diaphragm pathology in young but not adult dystrophic mdx mice.","volume":"176","author":"Murphy","year":"2010","journal-title":"Am J Pathol"},{"key":"R44-5-20211004","first-page":"3957","article-title":"Inhibition of myostatin reverses muscle fibrosis through apoptosis.","volume":"125","author":"Li","year":"2012","journal-title":"J Cell Sci"},{"key":"R45-5-20211004","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1469-7580.2012.01503.x","article-title":"Characterisation of connective tissue from the hypertrophic skeletal muscle of myostatin null mice.","volume":"220","author":"Elashry","year":"2012","journal-title":"J Anat"},{"key":"R46-5-20211004","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1089\/hum.2011.102","article-title":"Long-term systemic myostatin inhibition via liver-targeted gene transfer in golden retriever muscular dystrophy.","volume":"22","author":"Bish","year":"2011","journal-title":"Hum Gene Ther"},{"key":"R47-5-20211004","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1371\/journal.pgen.0030079","article-title":"A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs.","volume":"3","author":"Mosher","year":"2007","journal-title":"PLoS Genet"},{"key":"R48-5-20211004","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1111\/febs.12261","article-title":"Dysferlin-deficient muscular dystrophy and innate immune activation.","volume":"280","author":"Mariano","year":"2013","journal-title":"FEBS J"},{"key":"R49-5-20211004","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1517\/14728214.2012.691965","article-title":"Emerging drugs for Duchenne muscular dystrophy.","volume":"17","author":"Malik","year":"2012","journal-title":"Expert Opin Emerg Drugs"},{"key":"R50-5-20211004","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/mt.2011.59","article-title":"Current status of pharmaceutical and genetic approaches to treat DMD.","volume":"19","author":"Pichavant","year":"2011","journal-title":"Mol Ther"},{"key":"R51-5-20211004","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/mt.2010.212","article-title":"Antisense-induced myostatin exon skipping leads to muscle hypertrophy in mice following octa-guanidine morpholino oligomer treatment.","volume":"19","author":"Kang","year":"2011","journal-title":"Mol Ther"},{"key":"R52-5-20211004","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1755-8794-4-36","article-title":"Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy.","volume":"4","author":"Kemaladewi","year":"2011","journal-title":"BMC Med Genomics"},{"key":"R53-5-20211004","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1038\/mtna.2012.54","article-title":"Dual myostatin and dystrophin exon skipping by morpholino nucleic acid oligomers conjugated to a cell-penetrating peptide is a promising therapeutic strategy for the treatment of Duchenne muscular dystrophy.","volume":"1","author":"Malerba","year":"2012","journal-title":"Mol Ther Nucleic Acids"},{"key":"R54-5-20211004","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1469-7580.2010.01327.x","article-title":"Axon and muscle spindle hyperplasia in the myostatin null mouse.","volume":"218","author":"Elashry","year":"2011","journal-title":"J Anat"},{"key":"R55-5-20211004","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1002\/mus.23242","article-title":"Myostatin deficiency is associated with an increase in number of total axons and motor axons innervating mouse tibialis anterior muscle.","volume":"45","author":"Gay","year":"2012","journal-title":"Muscle Nerve"},{"key":"R56-5-20211004","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.neuint.2012.07.016","article-title":"Myostatin as a therapeutic target in amyotrophic lateral sclerosis.","volume":"61","author":"Walsh","year":"2012","journal-title":"Neurochem Int"},{"key":"R57-5-20211004","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.nmd.2011.10.012","article-title":"Transgenic inactivation of murine myostatin does not decrease the severity of disease in a model of spinal muscular atrophy.","volume":"22","author":"Rindt","year":"2012","journal-title":"Neuromuscul Disord"},{"key":"R58-5-20211004","doi-asserted-by":"crossref","first-page":"31245","DOI":"10.1093\/hmg\/ddp253","article-title":"Inhibition of myostatin does not ameliorate disease features of severe spinal muscular atrophy mice.","volume":"18","author":"Sumner","year":"2009","journal-title":"Hum Mol Genet"},{"key":"R59-5-20211004","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/hmg\/ddn426","article-title":"Delivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophy.","volume":"18","author":"Rose","year":"2009","journal-title":"Hum Mol Genet"},{"key":"R60-5-20211004","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ajpath.2010.10.035","article-title":"Inhibition of activin receptor type IIB increases strength and lifespan in myotubularin-deficient mice.","volume":"178","author":"Lawlor","year":"2011","journal-title":"Am J Pathol"},{"key":"R61-5-20211004","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1093\/gerona\/glt030","article-title":"Increased muscle force production and bone mineral density in ActRIIB-Fc-treated mature rodents.","volume":"68","author":"Chiu","year":"2013","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"R62-5-20211004","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1152\/japplphysiol.01183.2010","article-title":"Acute antibody-directed myostatin inhibition attenuates disuse atrophy and weakness in mice.","volume":"110","author":"Murphy","year":"2011","journal-title":"J Appl Physiol"},{"key":"R63-5-20211004","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1096\/fj.10-176917","article-title":"Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease.","volume":"25","author":"Zhang","year":"2011","journal-title":"FASEB J"},{"key":"R64-5-20211004","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1186\/1471-2164-13-541","article-title":"Ubiquitous Gasp1 overexpression in mice leads mainly to a hypermuscular phenotype.","volume":"13","author":"Monestier","year":"2012","journal-title":"BMC Genomics"},{"key":"R65-5-20211004","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.nmd.2012.07.002","article-title":"Identification of decorin derived peptides with a zinc dependent antimyostatin activity.","volume":"22","author":"Guiraud","year":"2012","journal-title":"Neuromuscul Disord"},{"key":"R67-5-20211004","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1245\/s10434-011-1720-5","article-title":"Changes in myostatin signaling in nonweight-losing cancer patients.","volume":"19","author":"Aversa","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"R69-5-20211004","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/ana.21338","article-title":"A phase III trial of MYO-029 in adult subjects with muscular dystrophy.","volume":"63","author":"Wagner","year":"2008","journal-title":"Ann Neurol"},{"key":"R70-5-20211004","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/mus.23539","article-title":"A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers.","volume":"47","author":"Attie","year":"2012","journal-title":"Muscle Nerve"},{"key":"R72-5-20211004","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/ng0696-189","article-title":"Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2.","volume":"13","author":"Johnson","year":"1996","journal-title":"Nat Genet"},{"key":"R73-5-20211004","doi-asserted-by":"crossref","first-page":"18551","DOI":"10.1074\/jbc.M111.338103","article-title":"Antihuman activin receptor-like kinase 1 (ALK1) antibody attenuates bone morphogenetic protein 9 (BMP9)-induced ALK1 signaling and interferes with endothelial cell sprouting.","volume":"287","author":"Van Meeteren","year":"2012","journal-title":"J Biol Chem"},{"key":"R74-5-20211004","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11926-013-0329-z","article-title":"Update on treatment of inclusion body myositis.","volume":"15","author":"Breithaupt","year":"2013","journal-title":"Curr Rheumatol Rep"},{"key":"R75-5-20211004","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1073\/pnas.0604893104","article-title":"Lack of myostatin results in excessive muscle growth but impaired force generation.","volume":"104","author":"Amthor","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R76-5-20211004","doi-asserted-by":"crossref","first-page":"E33","DOI":"10.1152\/ajpendo.00651.2012","article-title":"Lack of myostatin impairs mechanical performance and ATP cost of contraction in exercising mouse gastrocnemius muscle in vivo.","volume":"305","author":"Giannesini","year":"2013","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"R77-5-20211004","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1152\/japplphysiol.00126.2006","article-title":"Contractile properties of EDL and soleus muscles of myostatin-deficient mice.","volume":"101","author":"Mendias","year":"2006","journal-title":"J Appl Physiol"},{"key":"R78-5-20211004","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1152\/japplphysiol.00300.2010","article-title":"Grip force, EDL contractile properties, and voluntary wheel running after postdevelopmental myostatin depletion in mice.","volume":"109","author":"Personius","year":"2010","journal-title":"J Appl Physiol"},{"key":"R79-5-20211004","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/mus.21796","article-title":"Hindlimb skeletal muscle function in myostatin deficient mice.","volume":"43","author":"Gentry","year":"2011","journal-title":"Muscle Nerve"},{"key":"R80-5-20211004","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1152\/japplphysiol.00126.2011","article-title":"Decreased specific force and power production of muscle fibers from myostatin-deficient mice are associated with a suppression of protein degradation.","volume":"111","author":"Mendias","year":"2011","journal-title":"J Appl Physiol"},{"key":"R83-5-20211004","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1113\/jphysiol.2011.226001","article-title":"Myostatin inhibition induces muscle fibre hypertrophy prior to satellite cell activation.","volume":"9","author":"Wang","year":"2012","journal-title":"J Physiol"},{"key":"R84-5-20211004","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1113\/expphysiol.2011.063008","article-title":"Exercise training attenuates the hypermuscular phenotype and restores skeletal muscle function in the myostatin null mouse.","volume":"97","author":"Matsakas","year":"2012","journal-title":"Exp Physiol"},{"key":"R85-5-20211004","first-page":"223","article-title":"Food restriction reverses the hyper-muscular phenotype and force generation capacity deficit of the myostatin null mouse.","volume":"34","author":"Matsakas","year":"2013","journal-title":"Int J Sports Med"},{"key":"R86-5-20211004","doi-asserted-by":"crossref","first-page":"E2353","DOI":"10.1073\/pnas.1206410109","article-title":"Role of satellite cells versus myofibers in muscle hypertrophy induced by inhibition of the myostatinactivin signaling pathway.","volume":"109","author":"Lee","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R87-5-20211004","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1002\/jcb.23280","article-title":"Myostatin inactivation increases myotube size through regulation of translational initiation machinery.","volume":"112","author":"Rodriguez","year":"2011","journal-title":"J Cell Biochem"},{"key":"R88-5-20211004","doi-asserted-by":"crossref","first-page":"E993","DOI":"10.1152\/ajpendo.00509.2010","article-title":"Effect of postdevelopmental myostatin depletion on myofibrillar protein metabolism.","volume":"300","author":"Welle","year":"2011","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"R89-5-20211004","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1080\/02640414.2012.692480","article-title":"Human genetic variation: new challenges and opportunities for doping control.","volume":"30","author":"Schneider","year":"2012","journal-title":"J Sports Sci"},{"key":"R90-5-20211004","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1136\/bjsports-2012-091288","article-title":"Gene doping: an overview and current implications for athletes.","volume":"47","author":"Van der Gronde","year":"2013","journal-title":"Br J Sports Med"},{"key":"R91-5-20211004","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.cell.2010.11.039","article-title":"Short telomeres and stem cell exhaustion model Duchenne muscular dystrophy in mdxmTR mice.","volume":"143","author":"Sacco","year":"2010","journal-title":"Cell"},{"key":"R92-5-20211004","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/sj.onc.1207144","article-title":"Myostatin inhibits rhabdomyosarcoma cell proliferation through an Rb-independent pathway.","volume":"23","author":"Langley","year":"2004","journal-title":"Oncogene"},{"key":"R93-5-20211004","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.ejca.2010.12.010","article-title":"Differentiation of human rhabdomyosarcoma RD cells is regulated by reciprocal, functional interactions between myostatin, p38 and extracellular regulated kinase signaling pathways.","volume":"47","author":"Rossi","year":"2011","journal-title":"Eur J Cancer"},{"key":"R94-5-20211004","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1042\/BJ20112024","article-title":"Myostatin is a novel tumoral factor that induces cancer cachexia.","volume":"446","author":"Lokireddy","year":"2012","journal-title":"Biochem J"}],"container-title":["Current Opinion in Supportive & Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/01263393-201312000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T08:30:15Z","timestamp":1633509015000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01263393-201312000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":88,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/spc.0000000000000013","relation":{},"ISSN":["1751-4258"],"issn-type":[{"value":"1751-4258","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]}}}